Sign in
Taking people in United StatesPhase 1

Tests MRTX1719 in advanced solid tumors with a specific MTAP gene deletion

Tests MRTX1719 in adults with advanced solid tumors carrying an MTAP gene deletion.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Brookline, Chapel Hill, Chicago, Dallas, Fairfax, Fort Worth, Grand Rapids, Houston, Jacksonville, Lone Tree, Milwaukee, Mineola, Nashville, New Brunswick, New York, Norton Shores, Orlando, Phoenix, Port Jefferson Station, Rochester, San Antonio, Seattle, and Tyler, United StatesSee the 24 sites
Trial code
Registry title
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Status
Recruiting
Phase
Phase 1
People taking part
336 people, planned
Started
9 Jun 2022
Expected to end
10 Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • MRTX1719
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced solid tumor that cannot be removed by surgery or has spread, and whose tumor has a homozygous deletion of the MTAP gene.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Solid tumor that cannot be removed by surgery or has spread (unresectable or metastatic), confirmed under the microscope.
Earlier treatment
People who had earlier treatment with a PRMT5 or MAT2A inhibitor cannot join.
Biomarker or test result
Homozygous deletion of the MTAP gene found in tumor tissue.

Main reasons for not taking part

  • Earlier treatment with a PRMT5 or MAT2A inhibitor
  • Active brain metastases or carcinomatous meningitis
  • Significant coughing up of blood or bleeding within 4 weeks before the first dose
  • Major surgery within 4 weeks before the first dose
  • Bowel or stomach conditions that could change how the medicine is absorbed or make swallowing pills impossible

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue
  • Unresectable or metastatic disease
  • Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function

Who cannot take part

  • Prior treatment with a PRMT5 or MAT2A inhibitor therapy
  • Major surgery within 4 weeks of first dose of study treatment
  • History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications
  • Cardiac abnormalities
  • Active brain metastases or carcinomatous meningitis
  • Other protocol-defined Inclusion/Exclusion criteria apply

Where in United States

  • Dana-Farber Cancer InstituteBrookline, United StatesContact: Pasi Janne, Site 103Taking people
  • University of North CarolinaChapel Hill, United StatesContact: Shetal Patel, Site 125Taking people
  • University of North Carolina - Gastroenterology and HepatologyChapel Hill, United StatesContact: Shetal Patel, Site 107Taking people
  • Chicago, IllinoisHospital not named in the registryNo longer taking part
  • UT SouthwesternDallas, United StatesContact: Salwan Al Mutar, Site 120Taking people
  • Virginia Cancer Specialists PCFairfax, United StatesContact: Alexander Spira, Site 122Taking people
  • Texas Oncology - DFWFort Worth, United StatesContact: Andrew Paulson, Site 111Taking people
  • The Cancer & Hematology CentersGrand Rapids, United StatesContact: Sreenivasa Chandana, Site 106Taking people
  • MDACCHouston, United StatesContact: Jordi Ahnert, Site 105Taking people
  • Mayo ClinicJacksonville, United StatesContact: Hani Babiker, Site 114Taking people
  • Rocky Mountain Cancer Centers, LLP - OncologyLone Tree, United StatesContact: Robert Jotte, Site 109Taking people
  • Milwaukee, WisconsinHospital not named in the registryNo longer taking part
  • Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, United StatesContact: Kristen Spencer, Site 129Taking people
  • Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: Elizabeth Davis, Site 132Taking people
  • Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Kristen Spencer, Site 127Taking people
  • David H Koch, Memorial Sloan Kettering Cancer CenterNew York, United StatesContact: Kathryn Arbour, Site 104Taking people
  • Cancer and Hematology Centers of Western MichiganNorton Shores, United StatesContact: Sreenivasa Chandana, Site 131Taking people
  • Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, United StatesContact: Cesar Perez Batista, Site 121Taking people
  • Mayo ClinicPhoenix, United StatesContact: Tanios Bekaii-Saab, Site 113Taking people
  • New york cancer and blood specialists - OncologyPort Jefferson Station, United StatesContact: Richard Zuniga, Site 101Taking people
  • Mayo ClinicRochester, United StatesContact: Lei Deng, Site 112Taking people
  • South Texas Accelerated Research TherapeuticsSan Antonio, United StatesContact: Kyriakos Papadopoulos, Site 102Taking people
  • Seattle, WashingtonHospital not named in the registryNo longer taking part
  • Texas Oncology, P.A. - OncologyTyler, United StatesContact: Donald Richards, Site 110Taking people

About the trial

What the trial wants to find out

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

The 3 groups in the trial

  • Phase 1/1BTreatment being tested

    Dose Escalation/Evaluation

    Treatment: MRTX1719

  • Phase 1b Sub-studies 1-4Treatment being tested

    Treatment: MRTX1719

  • Phase 1b Sub-study 5Treatment being tested

    Treatment: MRTX1719

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Plain-language title
Tests MRTX1719 in advanced solid tumors with a specific MTAP gene deletionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 September 2026